filanesib + pomalidomide + dexamethasone

**Filanesib + pomalidomide + dexamethasone** is a combination regimen under investigation for the treatment of relapsed or refractory multiple myeloma. Filanesib (ARRY-520) is a small molecule inhibitor of kinesin spindle protein (KSP), which disrupts mitosis by inducing monopolar spindle formation, leading to cell cycle arrest and apoptosis in proliferating myeloma cells. Pomalidomide is an immunomodulatory agent that inhibits myeloma cell growth, angiogenesis, and enhances immune-mediated cytotoxicity. Dexamethasone is a synthetic glucocorticoid corticosteroid that augments the anti-myeloma effects of other agents and induces apoptosis in malignant plasma cells. The triple combination has shown synergistic activity in preclinical models, mediated by enhanced impairment of mitotic control and increased activation of proapoptotic proteins such as BAX, NOXA, BIM, and tBID[1][4][6]. This synergy results in mitochondrial outer membrane permeabilization and release of apoptogenic factors like cytochrome C[4]. Clinical trials are ongoing to evaluate its safety and efficacy in patients with relapsed/refractory multiple myeloma[1][6].

Brand names

Imnovid (for pomalidomide)Decadron (for dexamethasone)

Other names

none